Research Article

Baseline Chronic Kidney Disease and Ischemic Method of Partial Nephrectomy Are Important Factors for the Short- and Long-Term Deterioration in Renal Function for Renal Cell Carcinoma Staged T1-T2: A Retrospective Single Center Study

Table 1

Patient baseline demographics ( = 215).

ParameterMedian (range)Percentage or SD

Age (years)55 (24–78)
Gender (male/female)154/6171.6/28.4
BMI (kg/m2)24.7 (16.6–39.8)
Underlying disease
 Diabetes3214.9
 Hypertension8941.4
 Hypercholesterolemia94.2
 Ischemic heart disease52.3
Anticoagulation therapy history83.7
Aspirin therapy219.8
ASA score 0/1/2112/95/852.1/44.2/3.7
ECOG 0/1/2143/70/266.5/32.6/0.9
Smoking12156.3
Smoking volume (PY)8 (0–87)
Follow-up duration (mo)43 (12–134)
Preoperative laboratory findings
 Hemoglobin14 (8.6–17.5)
 Albumin4.6 (3.6–5.9)
 Calcium9.4 (8.3–10.9)
 Total Cholesterol185.5 (97–335)
 De Ritis ratio (AST/APT)1.1 (0.3–3.1)
 Creatinine1.0 (0.6–1.8)
Estimated GFR69.7 (37.3–103.4)
Preoperative PADUA score8.0 (5–12)
Tumor number2.4 (0.3–16)
Low/intermediate/high67/86/6231.2/40.0/28.8
Longitudinal: Inf/interpolar/med/mid/sup60/42/3/60/5027.9/19.5/1.4/27.9/23.3
RENAL score7 (3–18)
 Ant/post107/10849.8/50.2
Disease category
 Preoperative
  CKD RCC4621.4
  Non-CKD RCC14567.4
  Benign renal mass2411.2
Operative method
 Laparoscopy3315.4
 Open18284.6
Pathologic T stage
 T119389.8
 T22210.2
Fuhrman grade
 1209.3
 213160.9
 34320.0
 421.4
 Unknown198.8
Margin positive3014.0
Safety resection margin (mm)2.0 (1.0–9.0)
Ischemic method warm/cold/no131/42/4260.9/19.5/19.5
Ischemic time (min)21 (0–70)
Number of clamping vessels2 (1–4)
Tumor diameter (cm)2.0 (0.5–2.2)
Postoperative 5-year follow-up
 Creatinine1.6 (0.6–2.2)
 eGFR78.1 (29–118.8)
Histology
 Clear cell, pure16777.7
 Papillary167.4
 Chromophobe83.7
 Benign renal mass2411.2
Recurrence10.5
Time to recurrence52.1 (4.8–48.8)

SD, standard deviation; MSKCC, Memorial Sloane Kettering Cancer Center; LN, lymph node; F/U, follow-up; PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response; RECIST, Response Evaluation Criteria In Solid Tumors.